Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
- Weitere Titel
-
Zirkulierende und disseminierte Tumorzellen beim Mammakarzinom : Bericht von der Konsensuskonferenz Tumorzelldissemination im Rahmen der 39. Jahrestagung der Deutschen Gesellschaft für Senologie, Berlin, 27.06.2019
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Circulating and Disseminated Tumor Cells in Breast Carcinoma ; volume:79 ; number:12 ; year:2019 ; pages:1320-1327
Geburtshilfe und Frauenheilkunde ; 79, Heft 12 (2019), 1320-1327
- Beteiligte Personen und Organisationen
- DOI
-
10.1055/a-1031-1120
- URN
-
urn:nbn:de:101:1-2020022709421156967291
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T10:50:46+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Ähnliche Objekte (12)
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Update breast cancer 2023 Part 1 – early stage breast cancer
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Update breast cancer 2023 Part 1 – early stage breast cancer
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Update breast cancer 2023 Part 1 – early stage breast cancer